» Articles » PMID: 23096199

Genitourinary Imaging: Part 2, Role of Imaging in Medical Management of Advanced Renal Cell Carcinoma

Overview
Specialties Oncology
Radiology
Date 2012 Oct 26
PMID 23096199
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Renal cell carcinoma (RCC) comprises 80-85% of all primary renal neoplasms. Knowledge of the genetic and molecular features of RCC and the advent of molecular targeted therapy have revolutionized the treatment of RCC in the past decade. This article will review the changing role of the radiologist in the management of advanced RCC, especially in terms of the new relevance of RCC subtypes, treatment-related changes on imaging, new tumor response criteria, and commonly encountered molecular targeted therapy-related toxicities.

Conclusion: In this era of personalized cancer treatment, imaging has assumed a central role in treatment selection and follow-up of advanced RCC.

Citing Articles

Incidence and survival patterns of clear cell renal cell carcinoma from 2000 to 2017: A SEER Database Analysis.

Zou S, Cui L, Pai P, Lu Y, Li X, Wang G J Cancer. 2025; 16(5):1591-1597.

PMID: 39991582 PMC: 11843228. DOI: 10.7150/jca.105713.


Molecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.

Krajewski K, Braschi-Amirfarzan M, DiPiro P, Jagannathan J, Shinagare A Korean J Radiol. 2017; 18(1):28-41.

PMID: 28096716 PMC: 5240491. DOI: 10.3348/kjr.2017.18.1.28.


MRI phenotype in renal cancer: is it clinically relevant?.

Campbell N, Rosenkrantz A, Pedrosa I Top Magn Reson Imaging. 2014; 23(2):95-115.

PMID: 24690616 PMC: 4484274. DOI: 10.1097/RMR.0000000000000019.


Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer.

Leon L, Garcia-Figueiras R, Garcia-Figueras R, Suarez C, Arjonilla A, Puente J Target Oncol. 2013; 9(1):9-24.

PMID: 24338498 DOI: 10.1007/s11523-013-0304-7.